Currently Viewing:
Newsroom
Currently Reading
Inhaled Corticosteroid Use for COPD Treatment Linked to Increased Risk of Pneumonia
November 08, 2019 – Matthew Gavidia
Exposure to Disinfectants, Cleaning Products Linked to COPD Risk Among Female Nurses
October 29, 2019 – Matthew Gavidia
Study Finds Combination Therapy Reduces Number of COPD Exacerbations
October 25, 2019 – Alison Rodriguez
Long-Term Lung Damage Found In Ex-Smokers, Light Smokers
October 21, 2019 – Matthew Gavidia
Smart Mobile Health Tool May be Effective Alternative to Paper Action Plan for COPD
October 20, 2019 – Alison Rodriguez
Studies Look at COPD Care Management and Decision-Making Effectiveness
October 15, 2019 – Alison Rodriguez
High-Deductible Health Plans Linked With Financial Strain, More Frequent ED Visits for Patients With COPD
October 14, 2019 – Matthew Gavidia
Journal Retracts, Republishes COPD Study After Authors Find Intervention Created Harm, Not Benefit
October 08, 2019 – Allison Inserro
Wrist-Worn Step Trackers Shown to Accurately Predict Patient Health Outcomes
October 07, 2019 – Matthew Gavidia

Inhaled Corticosteroid Use for COPD Treatment Linked to Increased Risk of Pneumonia

Matthew Gavidia
The use of fluticasone-containing inhaled corticosteroids (ICS) was linked to increased risk of pneumonia in patients with COPD, according to study findings.
 
The use of fluticasone-containing inhaled corticosteroids (ICS) was linked to increased risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD), according to an October study published in International Immunopharmacology.

ICS are the typical treatment administered to patients with COPD who suffer from repeated exacerbations. A previous study exhibited associations between ICS treatment and an increased risk of developing pneumonia in patients with COPD, but evidence has remained controversial. Researchers sought to clarify the results of this link by conducting a meta-analysis of randomized controlled trials (RCT) derived from PubMed, Cochrane Library, ClinicalTrials.gov, and Embase between February 2019 and June 2019.

The incorporated RCTs compared ICS versus non-ICS treatment (long-acting beta agonists, long-acting muscarinic antagonists, or placebo) on the risk of pneumonia in patients with COPD. The meta-analysis included 25 trials comprising 49,982 patients, and the analysis was conducted by the Peto and Mantel-Haenszel approaches.

Pooled study results demonstrated a significant association for ICS usage and increased risk of pneumonia in patients with COPD (risk ratio [RR], 1.59; 95% CI, 1.33-1.90). ICS treatment was additionally shown to starkly increase the risk of severe pneumonia (RR, 2.17, 95% CI, 1.47-3.22), with the subgroup analysis based on doses of ICS showing consistent findings as well.

The results of the subgroup analysis based on types of ICS, however, showed that fluticasone therapy was associated with an increased risk of pneumonia in patients with COPD, while budesonide therapy was not. In medium and low-doses of budesonide treatment, no link was found for increased risk to pneumonia. The study authors said that this may be because “fluticasone could suppress effectively innate immunoresponse to bacterial triggers in alveolar macrophages,” as reported in previous studies, and that this effect “could be up to tenfold greater than that of budesonide in the human airway/lungs.” 

As many patients with COPD utilize ICS to inhibit exacerbations, delineating which type is effective in not only treating these issues but also in limiting related side effects in this patient demographic is crucial for quality care. Currently, the 5-year mortality rate for people with COPD typically ranges from 40% to 70%, while the 2-year mortality rate for people with severe COPD is approximately 50%. By avoiding complications deriving from a potentially fatal illness such as pneumonia, patients may benefit from improved quality of life and safer treatment.

Reference

Yang M, Du Y, Chen H, et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease [published online October 17, 2019]. Int Immunopharmacol. doi: 10.1016/j.intimp.2019.105950.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up